Daniel Joseph Oconnell Sells 8,143 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 8,143 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $1.82, for a total transaction of $14,820.26. Following the transaction, the chief executive officer owned 611,839 shares of the company’s stock, valued at approximately $1,113,546.98. The trade was a 1.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Monday, January 12th, Daniel Joseph Oconnell sold 5,388 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.73, for a total transaction of $9,321.24.
• On Friday, January 9th, Daniel Joseph Oconnell sold 12,941 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.76, for a total transaction of $22,776.16.
• On Wednesday, January 7th, Daniel Joseph Oconnell sold 37,755 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total transaction of $75,132.45.
• On Tuesday, January 6th, Daniel Joseph Oconnell sold 5,102 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.97, for a total transaction of $10,050.94.
• On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $9,158.53.

Acumen Pharmaceuticals Price Performance

Shares of NASDAQ ABOS opened at $1.73 on Wednesday. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.29. The stock has a fifty day simple moving average of $1.93 and a two-hundred day simple moving average of $1.69. Acumen Pharmaceuticals, Inc. has a 1-year low of $0.86 and a 1-year high of $2.46. The firm has a market cap of $104.79 million, a price-to-earnings ratio of -0.78 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. Analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

ABOS has been the subject of several recent research reports. Bank of America reduced their target price on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Friday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of large investors have recently modified their holdings of ABOS. SG Americas Securities LLC purchased a new position in Acumen Pharmaceuticals in the third quarter worth $691,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Acumen Pharmaceuticals in the 2nd quarter worth about $291,000. Jane Street Group LLC increased its position in shares of Acumen Pharmaceuticals by 1,526.0% during the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company’s stock valued at $204,000 after purchasing an additional 164,866 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Acumen Pharmaceuticals during the 2nd quarter valued at about $160,000. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Acumen Pharmaceuticals by 65.1% during the 3rd quarter. Bridgeway Capital Management LLC now owns 190,171 shares of the company’s stock valued at $325,000 after buying an additional 75,000 shares in the last quarter. 71.01% of the stock is currently owned by institutional investors.

More Acumen Pharmaceuticals News

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Analyst and institutional support — ABOS carries a consensus “Moderate Buy” from sell‑side analysts with a consensus price target near $6.75, and several institutions have recently built or increased stakes (Hudson Bay, SG Americas, Susquehanna, Bank of America). This underpins longer‑term demand and may limit downside. MarketBeat Coverage
• Neutral Sentiment: Short‑interest data is reported as effectively zero for Jan. 12, but the published figures contain inconsistencies (NaN); the short‑interest snapshot is unreliable and should not be relied on for explaining intraday moves. Monitor future updates for clarity.
• Neutral Sentiment: Insiders retain large holdings — despite recent sales, CEO Daniel O’Connell still owns ~593k shares, CFO Matt Zuga ~210k and COO Russell Barton ~123k. Large remaining insider stakes can be seen as alignment with shareholders even after sales.
• Negative Sentiment: Clustered insider selling — multiple senior executives sold shares between Jan. 5–12. CEO Daniel O’Connell sold ~26,472 shares across three trades (avg prices roughly $1.73–$1.82), CFO Matt Zuga sold 6,888 shares at $1.82 (and additional small sales earlier in the week), and COO Russell Barton sold 3,530 shares at $1.86. The concentration of sales (roughly ~37k shares total) is likely weighing on near‑term sentiment. SEC filings and press coverage: SEC Form 4 AmericanBankingNews: CEO sale
• Negative Sentiment: CFO’s repeated small sales — Matt Zuga executed multiple sales in early January (Jan. 5–8) at prices between ~$1.96–$1.82, totaling roughly $40k–$45k across those trades; repeated disposals can be interpreted negatively by active traders. Coverage: InsiderTrades alert

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.